Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
nrx-101 save search
NRx Pharmaceuticals, Inc. Announces New Data on NRX-101
Published: 2024-04-17 (Crawled : 14:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -0.93%
H: 0.94%
C: -1.88%
nrx-101
NRx Pharmaceuticals (NASDAQ:NRXP) Announces Data-Lock of Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-04-08 (Crawled : 12:30) - prnewswire.com
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 0.57%
H: 7.01%
C: 3.79%
nrx-101 depression treatment pharmaceuticals trial
NRx Pharmaceuticals (NASDAQ: NRXP) Announces Last Patient, Last Visit in its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-03-04 (Crawled : 13:30) - prnewswire.com
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -1.85%
H: 27.88%
C: 20.93%
nrx-101 depression treatment pharmaceuticals trial
NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) Announces Completion of Enrollment of its Phase 2b/3 Trial of NRX-101 in Suicidal Treatment Resistant Bipolar Depression
Published: 2024-01-22 (Crawled : 15:30) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 5.93%
H: 8.89%
C: -2.76%
nrx-101 depression treatment trial
NRx Pharmaceuticals Announces FDA Clearance of its Investigational New Drug (IND) Application for NRX-101 in the Treatment of Complicated Urinary Tract Infections
Published: 2023-12-18 (Crawled : 14:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 29.38%
H: 8.76%
C: -4.01%
nrx-101 fda drug treatment clearance pharmaceuticals application infections
Nkarta Presents NKX101 Clinical Data at the 2023 American Society of Hematology Annual Meeting & Exposition
Published: 2023-12-10 (Crawled : 04:20) - globenewswire.com
NKTX | $7.39 1.37% 1.35% 830K
|
Health Technology
| Email alert
Add to watchlist
nkx101 meeting
NRx Pharmaceuticals Announces Further Alignment with FDA on Initiation of Registrational Trials for NRX-101 in the Treatment of Chronic Pain
Published: 2023-10-26 (Crawled : 13:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 6.52%
H: 3.04%
C: 0.18%
nrx-101 fda treatment pharmaceuticals trials
NRx Pharmaceuticals Announces Strategic Change in Development of NRX-100 (IV Ketamine) at Dawson James Small Cap Investor Conference
Published: 2023-10-12 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 3.38%
H: 5.44%
C: 3.06%
nrx-100 conference change pharmaceuticals
NRx Pharmaceuticals Announces FDA Permission to Proceed on Investigational New Drug (IND) Application for NRX-101 to Treat Chronic Pain
Published: 2023-10-02 (Crawled : 19:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 4.81%
H: 5.72%
C: 5.36%
nrx-101 fda drug permission treat pharmaceuticals application
NRx Pharmaceuticals Announces Potent Antibacterial Activity of NRX-101 Against Common, Antibiotic Resistant Urinary Pathogens
Published: 2023-09-06 (Crawled : 18:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -1.71%
H: 12.22%
C: -1.15%
nrx-101 antibacterial pharmaceuticals pathogens
NRx Pharmaceuticals Announces Submission of an Investigational New Drug (IND) Application for NRX-101 in the Treatment of Chronic Pain
Published: 2023-08-30 (Crawled : 12:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -0.78%
H: 0.0%
C: -3.94%
nrx-101 drug treatment pharmaceuticals application submission
NRx Pharmaceuticals Announces the Licensure of a US Patent to Support Use of NRX-101™ for Chronic Pain
Published: 2023-08-07 (Crawled : 13:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 8.66%
H: 0.0%
C: -13.92%
nrx-101 patent pharmaceuticals
Nkarta Updates Clinical Progress of CAR-NK Cell Therapy NKX101 for Patients with Relapsed or Refractory Acute Myeloid Leukemia
Published: 2023-06-27 (Crawled : 11:00) - globenewswire.com
NKTX | $7.39 1.37% 1.35% 830K
|
Health Technology
|
| O: -3.31%
H: 1.14%
C: -35.84%
nkx101 cell leukemia therapy
Nkarta to Host Conference Call to Discuss Updated Clinical Data from NKX101 NK Cell Therapy Program
Published: 2023-06-26 (Crawled : 20:00) - globenewswire.com
NKTX | $7.39 1.37% 1.35% 830K
|
Health Technology
|
| O: -3.31%
H: 1.14%
C: -35.84%
nkx101 conference cell program therapy
NRx Pharmaceuticals, Lotus Pharmaceuticals and Alvogen Inc. Announce Collaboration to Develop and Commercialize NRX-101
Published: 2023-06-05 (Crawled : 11:00) - globenewswire.com
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -0.85%
H: 8.1%
C: -26.08%
nrx-101 pharmaceuticals collaboration
NRx Pharmaceuticals Announces Positive Recommendation to Continue Enrollment in the Ongoing Trial of NRX-101 in Patients with Suicidal Treatment-Resistant Bipolar Depression
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 4.12%
H: 1.3%
C: -4.32%
nrx-101 positive depression ongoing pharmaceuticals trial
NRx Pharmaceuticals Reports Minutes of Recent U.S. Food and Drug Administration (FDA) Meeting on the Development of NRX-101 to Treat Severe Bipolar Depression in Patients with Suicidality
Published: 2023-02-13 (Crawled : 16:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 0.0%
H: 4.46%
C: 1.79%
nrx-101 pharmaceuticals drug meeting food depression
NRx Pharmaceuticals Reports Recommendations of Data Safety Monitoring Board for Trial of NRX-101 in Patients with Severe Bipolar Depression and Subacute Suicidal Ideation or Behavior
Published: 2023-02-02 (Crawled : 12:00) - prnewswire.com
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: -0.85%
H: 6.84%
C: 6.84%
nrx-101 pharmaceuticals trial depression
NRx Pharmaceuticals Provides Progress Update on Interactions with the FDA regarding Path to NDA Submission for NRX-101
Published: 2023-01-19 (Crawled : 13:20) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 2.4%
H: 1.56%
C: -1.56%
nrx-101 fda pharmaceuticals update submission
NRx Pharmaceuticals Produces First Phase 3-stage NRX-101 Drug Made Using Commercial Process
Published: 2022-11-09 (Crawled : 13:00) - biospace.com/
NRXP 5 d | $3.01 -0.99% -1.0% 210K
|
Manufacturing
|
| O: 5.74%
H: 0.0%
C: -3.75%
nrx-101 pharmaceuticals drug commercial
Gainers vs Losers
| 75% | 25% |
Top 10 Gainers
MTTR | News M | $4.78 174.71% 63.6% 72M
|
AGBA | $2.565 105.2% 51.27% 200M
|
Finance
MLEC | $2.44 74.29% 42.62% 78M
|
n/a
EDBL | News | $6.28 67.02% 40.13% 16M
|
ATGL | $2.91 48.81% 32.8% 180K
|
ZAPP | $0.2175 47.16% 32.05% 16M
|
n/a
ONFO | $0.6075 38.38% 27.74% 7.3M
|
n/a
VIVK | $1.48 38.32% 27.7% 530K
|
Professional, Scientific, and T...
MNTS | $0.5 35.69% 26.3% 4.8M
|
SDIG A | $3.635 35.13% 26.0% 1M
|
Your saved searches
Save your searches and get alerts when important news are released.